Daily Stock Analysis, INO, Inovio Pharmaceuticals Inc, priceseries

Inovio Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
2.28
Close
2.19
High
2.35
Low
2.15
Previous Close
2.49
Daily Price Gain
-0.30
YTD High
5.11
YTD High Date
Jan 25, 2019
YTD Low
2.15
YTD Low Date
Aug 15, 2019
YTD Price Change
-2.03
YTD Gain
-48.10%
52 Week High
6.30
52 Week High Date
Oct 2, 2018
52 Week Low
2.15
52 Week Low Date
Aug 15, 2019
52 Week Price Change
-2.31
52 Week Gain
-51.33%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 11. 2017
6.75
May 30. 2017
7.63
12 Trading Days
13.01%
Link
LONG
Jan 22. 2018
4.64
Jan 29. 2018
4.88
5 Trading Days
5.15%
Link
LONG
Aug 21. 2018
4.54
Sep 13. 2018
5.31
16 Trading Days
16.86%
Link
LONG
Sep 25. 2018
5.05
Oct 5. 2018
5.42
8 Trading Days
7.31%
Link
LONG
Jan 3. 2019
4.28
Jan 14. 2019
4.61
7 Trading Days
7.63%
Link
LONG
Apr 2. 2019
3.70
Apr 16. 2019
3.96
10 Trading Days
7.05%
Link
Company Information
Stock Symbol
INO
Exchange
NasdaqGS
Company URL
http://www.inovio.com
Company Phone
858 597-6006
CEO
J. Joseph Kim
Headquarters
California
Business Address
10480 WATERIDGE CIRCLE, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001055726
About

Inovio Pharmaceuticals, Inc. is a bio pharmaceutical company. It develops active DNA immunotherapies for cancer and infectious diseases. The company's portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. Its pipeline consists vgx-3100, ino-3122, ino-3106, pennvax-b and pennvax-g. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Description

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The company's partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.